Differences among available immunoglobulin preparations for intravenous use.
Today almost all IgG preparations for intravenous use (IVIG) fulfill the basic requirements for a preparation given intravenously (sterility, pyrogenicity, antibody content but also anticomplementary activity, etc.). However, there are still marked differences among such preparations caused by the method of preparation: (1) Enzymatically treated IVIGs (by pepsin and plasmin) have a shorter biologic half-time and a disturbed IgG subclass composition; (2) in chemically treated IVIGs (beta-propiolactone, reduced or sulfonated IgGs) the IgG3 subclass is lacking and some of the Fc-related functions are altered; and (3) the IVIGs purified by anion exchangers are poor in the IgG4 subclass. The three main preparations sold in the United States (Gamimune N, Gammagard and Sandoglobulin) belong to the nonmodified preparations and, with the exception of the IgG subclass representation, show similar Fab- and Fc-related properties (antibody content, interaction with Fc receptors on monocytes, phagocytosis-promoting activity, etc.) In none of these preparations, an elevated level of undesired contaminants (prekallikrein activator, irregular anti-erythrocyte antibodies) are found.